Beigene Stock

Beigene Quick Ratio

Delisted·Jun 18, 2026

The Quick Ratio (Acid Test) of Beigene (6160.HK) as of Aug 17, 2026 is 2.59. In the previous year, Quick Ratio (Acid Test) was 1.30 — a change of 98.72% (higher).

Quick Ratio

2.59

YoY

98.72%

Last updated:

Quick Ratio (Acid Test) of Beigene is 2026 2.59 . Quick Ratio (Acid Test) of Beigene was 2025 1.30 . It decreases by 98.72% higher compared to the previous year.
Access this data via the Eulerpool API

Beigene Stock analysis

What does Beigene do? Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beigene stock

Quick Ratio (Acid Test) of Beigene is 2.59 in 2026.

Quick Ratio (Acid Test) of Beigene changed from 1.30 to 2.59, representing a 98.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Beigene since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Beigene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Beigene

All Key Metrics — Beigene